Multiple System Atrophy News and Research

RSS

Multiple-system atrophy (MSA) is a progressive neurological condition in which specific areas of the brain undergo neural degeneration. The three brain areas primarily affected are the brain stem, basal ganglia and cerebellum, portions of the brain that regulate bodily functions and motor control.

Brain diseases could have a greater societal impact than Covid-19, research finds

New research has found that brain diseases, such as Parkinson’s and Alzheimer’s, are surfacing earlier, proving more fatal, and could have a greater societal impact than Covid-19.

17 Aug 2021

Gene therapy shows promise in children with devastating genetic disorder

Children with a devastating genetic disorder characterized by severe motor disability and developmental delay have experienced sometimes dramatic improvements in a gene therapy trial launched at UCSF Benioff Children's Hospitals.

12 Jul 2021

Researchers uncover the mysteries of sleep disorders in multiple system atrophy

Multiple system atrophy (MSA) is a neurodegenerative disease with multiple debilitating symptoms. One of them is sleep disorders; however, owing to limited research, little is known about why only some patients are affected, how sleep disorders influence MSA severity, or even how sleep disorders vary across different MSA subtypes.

9 Apr 2021

Cleveland Clinic receives two grants to study therapeutic potential of anti-cancer drug in Alzheimer's

The National Institute of Aging, part of the National Institutes of Health, and the Alzheimer's Drug Discovery Foundation awarded five-year grants of $3.2 million and $1.4 million, respectively, to scientists from Cleveland Clinic Lou Ruvo Center for Brain Health to study the therapeutic potential of the anti-cancer drug lenalidomide in early-stage Alzheimer's disease, known as mild cognitive impairment.

27 Jan 2021

NIH awards $3.8 million to predict dementia in patients with Parkinson's disease

The National Institute of Neurological Disorders and Stroke at the National Institutes of Health has awarded a grant expected to total $3.8 million to Virendra Mishra, Ph.D., associate staff at Cleveland Clinic Lou Ruvo Center for Brain Health, to identify biomarkers - or disease indicators - to predict dementia in patients with Parkinson's disease.

6 Oct 2020

LRRK2 enzyme suppresses protein synthesis in Parkinson’s disease

In a recently published study, researchers from the Turku Bioscience Centre at the University of Turku and Åbo Akademi University in Finland monitored the production of new proteins as they were produced by the cells' protein building machinery, the ribosome.

15 Sep 2020

AFFiRiS AG announces results of phase 1 trial with PD01A in Parkinson's

AFFiRiS AG, a clinical-stage biotechnology company developing novel disease-modifying specific active immunotherapies (SAITs), today announced that detailed results of the phase 1 clinical program with its lead candidate PD01 in early Parkinson's disease (PD) patients were published in the peer-reviewed journal The Lancet Neurology.

18 Jun 2020

AFFiRiS announces preclinical results of monoclonal antibody mAB C6-17 in Huntington's

AFFiRiS, a clinical-stage biotechnology company developing novel disease-modifying specific active immunotherapies, today announced that detailed preclinical results with its monoclonal antibody mAB C6-17 to treat Huntington's Disease were published in the peer-reviewed journal Neurobiology of Disease.

3 Jun 2020

New technology distinguishes between two progressive neurodegenerative diseases

Scientists have found a way to distinguish between two progressive neurodegenerative diseases, Parkinson's disease and multiple system atrophy, using a technology developed by a researcher at The University of Texas Health Science Center at Houston.

6 Feb 2020

New recommendations aim to improve outcomes of Parkinson's disease patients

Since the discovery that the gut microbiome may play a role in the development of Parkinson's disease (PD), this fresh scientific approach has produced varying results. In this review published in the Journal of Parkinson's Disease scientists compare results of current research and provide recommendations to increase the comparability and utility of these studies with a view towards improving patient outcomes.

11 Nov 2019

Penn researchers to develop critical tool for imaging the brains of patients with Parkinson's

Researchers in the Perelman School of Medicine at the University of Pennsylvania will lead a multi-institutional effort in pursuit of developing a critical tool for imaging the brains of patients with Parkinson's and other neurodegenerative diseases.

10 Oct 2019

Newly discovered mechanism sheds light on how Parkinson’s disease can spread in the brain

Tiny channels between nerve cells are involved in a newly discovered mechanism of how Parkinson's disease can spread throughout the brain, according to new research from Linköping University, Sweden.

27 May 2019

Study on REM sleep disorder patients provides key predictors of Parkinson's disease

A large multi-centre study of more than 1,200 patients provides important predictors of Parkinson's disease progression, which will allow better candidate selection for clinical trials and more effective therapy development.

5 Mar 2019

Study finds risk factors linked to REM sleep behavior disorder

Taking antidepressants for depression, having post-traumatic stress disorder or anxiety diagnosed by a doctor are risk factors for a disruptive and sometimes violent sleep disorder called rapid eye movement (REM) sleep behavior disorder, according to a study published in the December 26, 2018, online issue of Neurology, the medical journal of the American Academy of Neurology.

27 Dec 2018

Experts in Parkinson's research propose roadmap for drug trials targeting alpha-synuclein

A recently discovered protein, alpha-synuclein, has become one of the most attractive targets for developing new drugs with the potential to slow down or arrest the progression of Parkinson's disease

20 Dec 2018

Inhibition of one protein clears toxic clumps seen in Parkinson's disease, study finds

A defining feature of Parkinson's disease is the clumps of alpha-synuclein protein that accumulate in the brain's motor control area, destroying dopamine-producing neurons.

14 Nov 2018

Study finds disease-causing mutation in French-Canadians

A team of Canadian scientists, including researchers at the Montreal Neurological Institute and Hospital has discovered the first French-Canadian founder mutation gene linked to synucleinopathies, a group of neurodegenerative diseases that includes Parkinson's disease, dementia with Lewy-Bodies and multiple system atrophy

1 Oct 2018

Electrical stimulation of the brain may help treat symptoms of neurodegenerative ataxias

Electrical stimulation of the brain and spinal cord may help treat the symptoms of rare movement disorders called neurodegenerative ataxias, according to a study published in the August 22, 2018, online issue of Neurology, the medical journal of the American Academy of Neurology.

23 Aug 2018

Targeting multiple proteins may be key to treat neurodegenerative disorders

Nearly all major neurodegenerative diseases - from Alzheimer's to Parkinson's - are defined and diagnosed by the presence of one of four proteins that have gone rogue: tau, amyloid-beta, alpha-synuclein, or TDP-43.

6 Jul 2018

Sleep disorders appear to be first sign of serious neurological diseases

Sleep disorders are often the first sign of serious neurological diseases. Neurologists should inquire extensively about the quality of their patients' sleep.

18 Jun 2018